Cortex cuts half its staff and narrows R&D focus
This article was originally published in Scrip
Executive Summary
Cortex Pharmaceuticals has cut its workforce by half in a restructuring that the firm says is "an absolute necessity" in the current financial climate. It plans to reduce its monthly cash burn and focus its resources towards its strongest near-term projects.